Trulieve Cannabis Corp. TRLV PHARMA
Company Overview
Trulieve Cannabis Corp. operates as a cannabis retailer in the United States. The company cultivates, processes, and manufactures cannabis products and distributes its products to its dispensaries, as well as through home delivery. It sells flowers, edibles, vapes, oral, topical, concentrates, and accessories under the Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, and Roll One brands. The company operates dispensaries in Florida, Arizona, Georgia, Ohio, Maryland, West Virginia, Connecticut, and Pennsylvania. It operates cultivation and processing facilities in Arizona, Colorado, Florida, Georgia, Maryland, Pennsylvania, and West Virginia. The company also offers medical cannabis dispensary in North Miami Beach, Florida. Trulieve Cannabis Corp. was formerly known as Schyan Exploration Inc./Exploration Schyan Inc. and changed its name to Trulieve Cannabis Corp. in September 2018. Trulieve Cannabis Corp. was incorporated in 1940 and is headquartered in Tallahassee, Florida.
Why Investors Should Care
Revenue has grown at a 36.1% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $1.18B (-0.4% YoY); net profit $-116.38M.
- Trailing 12 Months Year-on-year growth — revenue -10.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 36.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 36.11% |
| 1 Year: | -10.30% |
Stock Price Performance
| 1 Year: | +38.11% |
| 6 Months: | +94.22% |
| 3 Months: | -4.38% |
| 1 Month: | +42.06% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)73.89 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 36.1% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TRLV Trulieve Cannabis Corp. PHARMA | 12.43 | -5.09 | $2.12B | 0.00% | 5.77% | -47.65% | 36.11% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 96.06M | 120.77M | 136.27M | 193.82M | 215.12M | 224.09M | 317.75M | 313.84M | 295.35M | 285.21M | 281.80M | 275.21M | 297.62M | 303.44M | 284.28M | - | 297.76M | 302.09M | 288.19M | 293.15M | 286.75M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 114.54M | 119.16M | 118.33M | 117.98M | 116.67M |
| Gross Profit | 73.83M | 90.53M | 102.18M | 135.26M | 144.48M | 153.94M | 180.46M | 183.37M | 168.71M | 150.19M | 141.64M | 142.95M | 173.80M | 181.65M | 173.28M | - | 183.22M | 182.93M | 169.86M | 175.16M | 170.08M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 148.10M | 130.54M | 128.47M | 155.73M | 134.64M |
| Operating Income | 42.51M | 52.48M | 59.47M | 72.56M | 76.30M | 66.28M | 29.17M | 41.47M | -27.34M | 17.15M | -291.29M | 23.34M | 46.10M | 49.75M | 618.00K | - | 35.12M | 52.38M | 41.38M | 19.44M | 35.44M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 79.81M | 98.45M | 88.79M | 61.29M | 82.27M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.30M | 16.39M | 16.09M | 14.68M | 13.32M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.33M | 38.90M | 29.30M | 2.94M | 25.22M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 52.46M | 54.72M | 53.04M | 47.89M | 21.86M |
| Net Income | 23.61M | 18.94M | 17.41M | 30.08M | 40.88M | 18.62M | -32.48M | -24.02M | -115.07M | -67.14M | -406.87M | -25.84M | -24.52M | -11.98M | -61.60M | - | -32.87M | -13.78M | -26.84M | -42.90M | 2.41M |
| Diluted EPS | 0.20 | 0.16 | 0.15 | 0.24 | 0.31 | 0.14 | -0.16 | -0.09 | -0.38 | -0.18 | -1.80 | -0.12 | -0.16 | -0.04 | -0.32 | - | -0.17 | -0.07 | -0.14 | -0.22 | 0.01 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 252.82M | 521.53M | - | 1.22B | 1.13B | 1.19B | 1.18B |
| Cost of Revenue | - | - | - | 529.10M | 540.57M | 470.75M | 470.01M |
| Gross Profit | 191.84M | 386.42M | - | 689.13M | 588.63M | 715.75M | 711.17M |
| Operating Expenses | - | - | - | 563.41M | 495.99M | 623.26M | 562.85M |
| Operating Income | 113.27M | 218.30M | - | 125.71M | 92.64M | 92.49M | 148.32M |
| EBITDA | - | - | - | 239.75M | -32.31M | 271.28M | 328.33M |
| Interest Expense | - | - | - | 73.42M | 81.57M | 62.19M | 63.45M |
| Pretax Income | - | - | - | -19.24M | -284.54M | 42.71M | 91.47M |
| Tax Provision | - | - | - | 163.38M | 151.36M | 197.59M | 208.11M |
| Net Income | 53.09M | 63.00M | - | -246.06M | -526.80M | -155.10M | -116.38M |
| Diluted EPS | 0.46 | 0.53 | - | -1.31 | -2.79 | -0.82 | -0.61 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 809.78M | - | 3.40B | 2.73B | 2.87B | 2.70B |
| Current Assets | - | - | - | - | 593.54M | 477.35M | 604.56M | 562.72M |
| Cash & Equivalents | - | 91.81M | 146.71M | - | 207.19M | 201.37M | 238.80M | 255.53M |
| Inventory | - | - | - | - | 276.50M | 213.12M | 231.37M | 242.30M |
| Receivables | - | - | - | - | 6.51M | 6.70M | 8.29M | 10.50M |
| Total Liabilities | - | - | 361.87M | - | 1.47B | 1.32B | 1.62B | 1.55B |
| Current Liabilities | - | - | 76.12M | - | 210.29M | 114.85M | 138.49M | 126.94M |
| Long Term Debt | - | - | - | - | 635.91M | 479.07M | 476.78M | 227.58M |
| Total Debt | - | - | - | - | 975.06M | 792.57M | 824.46M | 563.62M |
| Total Equity | 78.81M | 132.88M | 447.90M | - | 1.93B | 1.41B | 1.26B | 1.16B |
| Shares Outstanding | - | - | - | - | 185.99M | 186.24M | 191.01M | 192.31M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 19.07M | 99.64M | - | 23.10M | 201.84M | 271.48M | 272.82M |
| Investing Cash Flow | -94.67M | -174.65M | - | -215.06M | -37.47M | -206.62M | 13.50M |
| Financing Cash Flow | 142.98M | 129.91M | - | 177.80M | -175.59M | -33.44M | -270.50M |
| Capital Expenditure | -71.83M | -99.94M | - | -193.80M | -50.85M | -147.66M | -60.51M |
| Free Cash Flow | -52.76M | -298.00K | - | -170.70M | 150.99M | 123.82M | 212.31M |
| Net Change in Cash | - | - | - | -15.85M | -5.81M | 31.73M | 15.82M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | 75.9% | 74.1% | - | 56.6% | 52.1% | 60.3% | 60.2% |
| Operating Margin % | 44.8% | 41.9% | - | 10.3% | 8.2% | 7.8% | 12.6% |
| Net Margin % | 21.0% | 12.1% | - | -20.2% | -46.7% | -13.1% | -9.9% |
| ROE % | 40.0% | 14.1% | - | -12.7% | -37.2% | -12.3% | -10.0% |
| ROCE % | - | 29.8% | - | 3.9% | 3.5% | 3.4% | 5.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | AdvisorShares Investments, LLC | 6.25% | 10.64M | $117.80M |
| 2 | Nomura Holdings Inc. | 2.98% | 5.07M | $56.08M |
| 3 | Cantor Fitzgerald, L.P. | 2.20% | 3.75M | $41.51M |
| 4 | Marex Group Ltd. | 1.91% | 3.25M | $35.98M |
| 5 | ING Groep N.V. | 1.57% | 2.67M | $29.50M |
| 6 | Oakmont Corp | 0.89% | 1.51M | $16.68M |
| 7 | Jane Street Group, LLC | 0.71% | 1.21M | $13.42M |
| 8 | Picton Mahoney Asset Management | 0.49% | 838.09K | $9.28M |
| 9 | iA Global Asset Management Inc. | 0.31% | 522.99K | $5.79M |
| 10 | Anson Funds Management LP | 0.31% | 524.50K | $5.81M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TRLV
TRLV Price Today: Trulieve Cannabis Corp. Stock Price, Quote & Chart | MEXC - mexc.co
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9UUnBiY2JkZTYtbFJ0X1ByenZzVkg0V2dTSW03cTFwSldyY2NCSngzRFg3SEw2Ri13UUlYRk90YXZnSm5JS3c?oc=5" target="_blank">TRLV Price Today: Trulieve Cannabis Corp. Stock Price, Quote & Chart | M…
Trulieve Cannabis (TRLV) Stock Price, News & Analysis - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTE9pbHJta09fWFM2YnlYMnNnLVZQc0s2Z09maDhUelp0U2sxSDhsVUtELU4xZ24xdTZ3RXpLSUFXM1NEaWV6c0VKcDh6d2pQUkdwX2M0?oc=5" target="_blank">Trulieve Cannabis (TRLV) Stock Price, News & Analysis</…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE5RSnFFZHpjTGcwQjlIOFhZSDBxWVB5R1FJMDY0cHhjSWR3Mm1PLW5NOVFoYThYdWFNeGFSYjFQYUE1RUlUWWF0VkY0N3lZNEk2?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Is Trulieve (TRLV) Using Georgia’s Dunwoody Launch To Redefine Its Medical-Centric Growth Strategy? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxQSHZlZWNzM0lsZUJESklQdkR1UEU3SGtWVWFGdmNyXzFXYThKNlZoOTlFZGk2NUN3SFBza0ZUUHh2bEpYM3QxWHB5ZWN2Y190Z0RJLW9HdUhLWjk0QjJfeFlZY05oRnN2SkdBLWZNRW9VbVBmWFFtdzlVQU1wRENqNTJEbW5PM1FVb3JNRW…
TRLV Stock Price and Chart — NYSE:TRLV - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE9menBFTHpEREtvNmYxOXRsczRieDFuOTYybDlCS3VPempWcWxBU012Y1RQUXdIS1FkTG1mckJHX3NIZ0VhZWlNWnp4VTd2amVOMVUwc0tYV2hadw?oc=5" target="_blank">TRLV Stock Price and Chart — NYSE:TRLV</a>&nb…
Trulieve Announces Uplist to NYSE - Jun 5, 2026 - Investors - Trulieve
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxPR3NSak92TVc2SElNdTdFTkg0VGMwWlNZXzBfY3d6MHZVUWhNME9UQWl4ZUxiT1JFeVc2UmpVTTRMZnF6ZUlUWGV6Ulc5V1gwUFJFeWlMUll4VVdfaEdXSGZQc1QtUUxwZlpqS1pwSkVHal9GSmdYY205NFJSZV9NQw?oc=5" target="_…
TRLV — Frequently Asked Questions
What is the current share price of Trulieve Cannabis Corp. (TRLV)?
As of 2026-09-19 21:16 PDT, Trulieve Cannabis Corp. (TRLV) trades at $12.43 on NYSE. Its 52-week range is $4.76 to $13.00.
What is the market capitalisation of TRLV?
Trulieve Cannabis Corp. (TRLV) has a market capitalisation of $2.12B on NYSE.
What is the P/E ratio of TRLV?
TRLV trades at a trailing price-to-earnings (P/E) ratio of -5.09. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.82.
What is the return on equity (ROE) of TRLV?
TRLV has a return on equity (ROE) of -47.65%. Its return on capital employed (ROCE) is 5.77%.
Is TRLV a good stock to buy?
This page provides a data-driven analysis of Trulieve Cannabis Corp. (TRLV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.